Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etrasimod in Primary Biliary Cholangitis
NCT03155932Phase 2Terminated
- Sponsor
- Arena Pharmaceuticals, Inc.
- Start
- Dec 2017
- Primary completion
- Jan 2019
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of etrasimod in primary biliary cholangitis (PBC), sponsored by Arena Pharmaceuticals, Inc. Primary endpoints: Serum Alkaline Phosphatase Concentration at Week 24 and Number of Participants With Adverse Events. Started Dec 2017; status: terminated.
02
Drugs
etrasimod
03
Conditions
primary biliary cholangitis (PBC)
Beyond the preview
Go deeper on NCT03155932.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03155932.